BridgeMD
New treatment option for Ischemic Stroke
Official title Ambulatory Stroke Unit Treatment for Elderly Patients
ClinicalTrials.gov ID: NCT07420374
What this study is testing
- What it's testing
- ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits. Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 and older
You may be able to join if
- Age ≥ 60 years
- Diagnosis of acute ischemic stroke (ICD-10 I63.), transient ischemic attack (G45.), or retinal ischemia (H34.\ )
- Symptom onset ≤ 7 days before enrollment
- No or non-disabling newly occurring neurological deficit allowing safe ambulatory management
- Written informed consent provided by the participant or, if lacking decision-making capacity, by a legally authorized representative
You likely can't join if
- Requirement for urgent surgical or treatment secondary prevention (e.g., carotid revascularization)
- Fluctuating stroke symptoms within the previous 48 hours
- Acute febrile infection or isolation-requiring infectious disease
- Clinically relevant dysphagia with high aspiration risk
- Critical medical or nursing findings requiring mandatory multi-day inpatient treatment
- Palliative care situation with limitation of acute diagnostic or therapeutic measures
See the full eligibility criteria
- Age ≥ 60 years
- Diagnosis of acute ischemic stroke (ICD-10 I63.), transient ischemic attack (G45.), or retinal ischemia (H34.\ )
- Symptom onset ≤ 7 days before enrollment
- No or non-disabling newly occurring neurological deficit allowing safe ambulatory management
- Written informed consent provided by the participant or, if lacking decision-making capacity, by a legally authorized representative
- Requirement for urgent surgical or treatment secondary prevention (e.g., carotid revascularization)
- Fluctuating stroke symptoms within the previous 48 hours
- Acute febrile infection or isolation-requiring infectious disease
- Clinically relevant dysphagia with high aspiration risk
- Critical medical or nursing findings requiring mandatory multi-day inpatient treatment
- Palliative care situation with limitation of acute diagnostic or therapeutic measures
- Previous participation in the ambulatory stroke unit care model
- No statutory health insurance coverage in Germany
- Insufficient German language proficiency to understand study procedures and assessments
The study team makes the final eligibility decision.
Where it's taking place
- Heidelberg, Germany
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Heidelberg, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.